Elizabeth Mack
University of Nebraska Medical Center
5 Papers
25 Citations
Elizabeth Mack is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Serotonin receptor binding affinities of several hallucinogenic phenylalkylamine and N,N-dimethyltryptamine analogues.
TL;DR: The most behaviorally potent analogues examined, DOB, DOM, and 5-methoxy-N,N-dimethyltryptamine, were found to possess rather high affirmities for the 5-HT receptors of the model system.
35
Radiolabeled cyclosaligenyl monophosphates of 5-iodo-2'-deoxyuridine, 5-iodo-3'-fluoro-2',3'-dideoxyuridine, and 3'-fluorothymidine for molecular radiotherapy of cancer: synthesis and biological evaluation.
TL;DR: In vitro studies indicate that radiation doses delivered to the cell nucleus are sufficient to kill cells of several difficult to treat malignancies including glioblastoma and ovarian and colorectal cancers.
17
Preclinical evaluation of investigational radiopharmaceutical RISAD-P intended for use as a diagnostic and molecular radiotherapy agent for prostate cancer
Zbigniew P. Kortylewicz,Elizabeth Mack,Charles A. Enke,Katherine A. Estes,R. Lee Mosley,Janina Baranowska-Kortylewicz +5 more
TL;DR: The preclinical toxicity and targeting potential of RISAD‐P was evaluated and the reagent was approved for molecular radiotherapy with Auger electron‐emitting radionuclides.
6
Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer.
Michio Abe,Zbigniew P. Kortylewicz,Charles A. Enke,Elizabeth Mack,Janina Baranowska-Kortylewicz +4 more
TL;DR: Findings indicate that therapies targeting pancreatic cancer stromal components may have unintended mitogenic effects and that these effects can be reversed when imatinib is used in conjunction with radioimmunotherapy.
6